Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants)

FDA Approved
Related tests:


23andMe Personal Genome Service (PGS) Risk Report for BRCA1/BRCA2 (Selected Variants) is a qualitative non-invasive DNA genetic test for detection of select BRCA1 and BRCA2 SNPs. The test is intended for users ≥ 18 years old. It uses qualitative genotyping to detect select clinically relevant variants in genomic DNA isolated from human saliva collected from individuals ≥18 years with the Oragene Dx model OGD500.001 for the purpose of reporting and interpreting genetic health risks. It is indicated for reporting of the 185delAG and 5382insC variants in the BRCA1 gene and the 6174delT variant in the BRCA2 gene. It detects only three variants and does not detect all genetic variants in these genes associated with increased risk of developing breast, ovarian or prostate cancer. There are more than 1,000 different BRCA1/BRCA2 variants known to be associated with increased risk of developing cancer. The absence of a variant tested does not rule out the presence of other genetic variants that may be disease-related.
Breast Cancer, Male Breast Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer
BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset)